Melioidosis, an endemic disease in northern Australia and south-east Asia, is caused by the soil saprophyte Burkholderia pseudomallei. The indirect hemagglutination assay (IHA) is the most frequently used serological test to help confirm exposure to the causative organism.
deep brain abscesses). It may also provide supportive information if melioidosis is suspected 25
but the organism fails to grow. Simple, rapid and reliable serological tests for melioidosis 26 hold the possibility of identifying cases earlier and thereby improving outcomes, given that 27 culture and identification of B. pseudomallei can be delayed. 28
29
The indirect hemagglutination assay (IHA) has been the mainstay of serological testing for 30 melioidosis over many years and the technique has remained largely unchanged since first 31 described over 40 years ago (16) . Despite variable sensitivity and specificity, it remains the 32 most commonly employed serological test, with titres of 1:40 or greater considered reactive 33 in Australia (3) . High background rates of seropositivity have been described in endemic 34 areas and can affect the utility of the test (22) . In north Queensland, rates of background 35 IHA seropositivity in the population are relatively high and have ranged from 2.5% in 36 asymptomatic blood donors (20) to 5.7% in samples from the district pathology laboratory 37 (3) . of IgM and IHA testing has been shown to provide a sensitivity of 100% and specificity of 56 95.4% when used in the diagnosis of acute melioidosis in an endemic area (19) . However, 57
other studies have found detection of IgG more useful in the serodiagnosis of acute disease 58 (14, 9) . Polymerase chain reaction (PCR) based assays have been developed and appear 59 promising, though lacking in sensitivity (15) . 60
61
This study aimed to describe the patterns of serological responses to culture-confirmed 62 melioidosis observed in our area. Specifically, we were interested to examine the patient 63 factors associated with a failure to mount a detectable antibody response despite culture-64 confirmed disease. Failure to mount an IHA response could conceptually correlate with 65 demographic factors (such as age, ethnicity or gender), co-morbid conditions (such as 66 diabetes, renal failure or steroid use), bacteraemia or chronic disease. Indeed, previous work 67 in northern Australia demonstrated that an initially negative IHA result was predicted by the 68 presence of pneumonia, positive blood cultures or female gender (7) . However, the presence 69 of a persistently negative IHA has not been found to correlate with any measured patient 70 tested based on the method described by Jewell (17) . Significance of the Relative Risk was 107 assessed as significant at P<0.05, if the 95% confidence limits did not reach 1 (11). A 108 similar analysis was performed on data relating to admission IgG EIA. The data on the 109 relationship between clinical features and serial IHA responses were placed into two by four 110 contingency tables. As the average expected frequency was greater than six, a χ 2 analysis 111 was appropriate. Significant outcomes were retested by using a log-likelihood ratio for 112 contingency tables (G statistic) as a confirmatory test with an adjustment for small sample 113 size (17, 25) . Although serial EIA tests were performed on a number of patients, the sample 114 was too small to perform a meaningful statistical analysis of longitudinal IgG responses. was 53 years, with a range from 6 to 88 years. Five (4%) of patients were in the paediatric 123 age group (defined as ≤15 years). Of the total number of patients, 81 (57%) were bacteremic 124 at presentation, 14 (10%) went on to experience true disease relapses and 32 (23%) patients 125 died. The lung was the most common organ involved (Table 1) 
